The Phase III portion of the companies' trial of Kevzara will now only enroll critically ill patients and randomize them to receive the drug at 400mg or placebo, after the drug did not appear effective in severely ill patients.
An official form Northwell Health said trials of Gilead and Regeneron drugs were able to get up and running in four days rather than taking months to start, in part because clinical trials in other disease areas have been put on hold.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases